Trends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals
|
|
- Magnus Richard
- 6 years ago
- Views:
Transcription
1 Trends in Hepatitis C Virus Infection Therapy: Protease Inhibitors a Step Forward in the Era of Direct Acting Antivirals CRISTINA POPESCU 1, 2, SMARANDA GLIGA 1, VICTORIA ARAMĂ 1, 2 1 Matei Bals National Institute of Infectious Diseases, Bucharest, Romania 2 Carol Davila University of Medicine and Pharmacy, Bucharest, Romania The standard of care for the treatment of HCV infected patients was until 11 the association peginterferon-ribavirin with a sustained virologic response of 5%. In 11 another class of antivirals was approved by the FDA and EMEA the HCV-NS3 protease inhibitors. Two molecules are now available: boceprevir and telaprevir. The protease inhibitors are used in association with peginterferon and ribavirin, which remain vital therapy components. Protease inhibitor regimens substantially increased the rate in naïve patients and also in previously relapse patients. Because of the high risk of emerging resistance to protease inhibitors, prior null responders are not yet suitable candidates for triple therapy, the rate in these patients is still very low. Keywords: protease inhibitor, HCV, treatment, sustained virologic response. A. INTRODUCTION B. BACKGROUND Chronic HCVinfection is an important public health problem, affecting more than million people globally (approximately 3% of the global population), patients infected being at risk for progression to cirrhosis (3%) and hepatocellular carcinoma (5%) [1]. What is vital to know is that HCV infection can be cured, the cure rate depending also on the accuracy of antiviral treatment administration. Recent years have signalled a real effervescence regarding introduction of new antiviral drugs, especially the ones with direct antiviral action (DAA direct acting antiviral). Because the response rate to the current standard of care is around 5% [2], two important problems need solving in the near future: improving treatment response for naïve patients and finding new therapeutic solutions for previously treated patients, with therapy failure. The introduction of protease inhibitors represents a major step in managing patients infected with HCV genotype 1, widely accepted as the most frequently involved and difficult to treat viral genotype [3]. The major purpose of antiviral therapy in HCV infected patients is obtaining Sustained Virologic Response (), i.e. demonstrating undetectable HCV viral load, 6 months after completion of therapy. Treatment of HCV infection has consistently improved since The rate has continually increased through permanent changes made to the STANDARD of CARE (SoC). Thus, from the introduction of standard interferon monotherapy with a duration of 6 months and an of 6%, therapy has changed permanently in order to increase the cure rate. Ribaviarin was the first milestone along the road, which caused an additional 3%. A second milestone was pegylated interferon with improved pharmacokinetic and pharmacodynamic qualities, adding 25% of versus standard interferon [4]. Increasing the rate of to 75 % by adding IP to SoC is clearly a step forward in the fight against HCV (Fig. 1). In addition, a better knowledge of the adverse effects of antiviral drugs in adjunction to supportive medication (erythropoietin) determines a lower rate of therapeutic discontinuation and obviously improves the rate. ROM. J. INTERN. MED., 12, 5, 2,
2 118 Cristina Popescu et al. 2 PEG-RBV-PI PEG-RBV 12 m 54 PEG 12 m 39 IFN-RBV 12 m IFN-RBV 6 m IFN 12 m 16 IFN 6 m Fig. 1. History of HCV treatment. C. USE OF PROTEASE INHIBITORS IN CHRONICALLY HCV INFECTED PATIENTS Improved knowledge of the HCV life cycle, its complex structure, led to the discovery of new compounds, so-called Directly acting antiviral agents (DAA). Among the many molecules that are currently under evaluation, two molecules belonging to the IP class receive extensive studies including Phase III trials, and were recently introduced in international treatment guidelines, for both naïve and previously treated patients in therapy failure. We are talking about boceprevir (approved for use in May 11 in the and July 11 in the EU) and telaprevir (approved for use in May 11 in the and September 11 in the EU). We cannot predict when the rest of the molecules under study will be used in the treatment of HCV infection. If we were to consider what happens overall to HCV chronically infected patients following the current SoC, we could say that: 5% register 25% are relapsers % are non-responders 5% register breakthrough (Fig. 2). Because only half of HCV chronically infected patients have a favorable response to the current regimen, the need for new molecules that can improve rates is self-evident. RESPONSE RATE 1 patients 5 patients RVS 5 patients non-rvs 99% undetectable at 5 years 25 relapse 5 breakthrough null responders Failure Require re-treatment Fig. 2. The virologic response after PEG-RBV.
3 3 Trends in Hepatitis C Virus Infection Therapy 119 C.1. USING PI IN NAIVE PATIENTS a. Using boceprevir in naive patients Boceprevir is the first PI introduced in the treatment of HCV infection. The efficacy of boceprevir in treating naïve patients was demonstrated by clinical trials: SPRINT 1 [5] (Phase 2) and SPRINT 2 [6] (Phase III) that led to the approval of its marketing. The SPRINT I study followed the safety, tolerability and antiviral effectiveness of boceprevir in combination with peg interferon and ribavirin and included 5 naïve patients who were randomly assigned in one of the 5 groups: peginterferonribavirin for 48 weeks (PR48w), boceprevirpeginterferon-ribavirin for 24 weeks (BPR24w), boceprevir-peginterferon-ribavirin for 48 weeks (BPR48w), 4 weeks lead-in with peginterferonribavirin then boceprevir-peginterferon-ribavirin for 24 weeks (PR4w/BPR24w) and 4 weeks lead-in with peginterferon-ribavirin then boceprevir-peginterferon-ribavirin for 44weeks (PR4w/BPR44w). Figure 3 shows the rates, according to the treatment regimens that were used. The best rate was achieved with lead-in regimen followed by triple therapy for 44 weeks. The addition of boceprevir to PR is associated with an improved of 37% PR48 BPR 24 BPR48 PR4/BPR24 PR4/BPR44 Fig. 3. The effectiveness of triple therapy using boceprevir, with different regimens. In the phase III SPRINT 2 study 197 naïve patients were included, subsequently randomised in three arms, after a lead- in period of 4 weeks with PR: the first arm with PR and placebo; the second arm used response guide therapy with BPR for 24 weeks, then PR for another weeks and the third arm with 44 weeks of BPR. rates were 38% for arm 1, 63% for arm 2 and 66% for arm 3. Both SPRINT studies demonstrated an additional rate of at least 25%. b. Using telaprevir in naive patients PROVE 1 [7] and PROVE 2 [8] studies evaluated telaprevir- peg interferon- ribavirin (TPR) triple therapy regimens in patients infected with genotype 1 virus. PROVE 1 included 233 patients randomized in one of the three arms. Patients who had received peg interferon- ribavirin (PR) placebo for 48 weeks were included in the control group. Patients who received telaprevir were divided as follows: 12 wks telaprevir + 12 wks PR 12 wks telaprevir + 24 wks PR 12 wks telaprevir + 48 wks PR The rates are presented in Fig. 4. The highest rate was obtained with the 12 week triple therapy regimen followed by 36 weeks of PR. PROVE 2 study enrolled 334 naïve patients, who received various regimens containing telaprevir. The results were similar to the PROVE 1 study. The regimen with the highest was the 12 week telaprevir- peginterferon-ribavirin, followed by 36 weeks of peg interferon- ribavirin. Both PROVE 1 and PROVE 2 studies have shown that shortening the duration of antiviral treatment with peg interferon-ribavirin lowers the rate. In addition, these studies emphasized the role of ribavirin in reducing the risk of relapse and breakthrough.
4 1 Cristina Popescu et al PEG-RBV-placebo 12T12PR 12T24PR 12T48PR Fig. 4. The effectiveness of different triple therapy regimens with telaprevir. The Phase 3 ADVANCE [9] study enrolled 188 patients who were divided into three arms: arm 1 with PR and placebo for 48 weeks (PR48w), arm 2 8 weeks triple therapy followed by response guided duration of PR (T8PR) and arm 3 12 weeks triple therapy, followed by response guided duration of PR (T12PR). Patients with undetectable viral loads at 4 and 12 weeks, received only 24 weeks of treatment. Those with positive viral loads at 4 weeks received 48 weeks of treatment. The best rate was achieved for patients who received 12 weeks of telaprevir (75% vs. 69% if telaprevir was given for 8 weeks) (Fig. 5). These three studies were the basis for the approval of telaprevir marketing. In 11 the results of the ILLUMINATE [1] study were published. This study included 5 naïve patients who received 12 weeks of TPR followed by response guided therapy with PR. The patients with extended rapid virologic response (E-RVR undetectable viral load at weeks 4 and 12 of TPR) were randomly assigned in one of the two groups: T12PR24 and T12PR48. All the patients without received 48 weeks of PR. The rates for the patients with E-RVR were 92% for T12PR24 arm and 88% for T12 PR48 arm, establishing noninferiority of short treatment for the patients with E-RVR PR48 T8PR T12PR Fig. 5. The effectiveness of triple therapy regimens with telaprevir and response guided therapy PR. C.2. USING PIS IN EXPERIENCED PATIENTS About half the patients treated with PEG- RBV fail to achieve. These patients require re-treatment with new molecules that improve the response rate. Patients who have failed previous therapies can be grouped into: Relapser patient with undetectable viral load (VL) at end of treatment but detectable VL after 6 months of follow-up Partial virologic response reduction of VL with at least 2log1 after 12 weeks of treatment, but not undetectable VL Null- responders reduction of VL with less than 2log1 after 12 weeks of treatment.
5 5 Trends in Hepatitis C Virus Infection Therapy 121 a. Using boceprevir in previously treated patients The RESPOND-2 (11) study enrolled 3 experienced patients in therapeutic failure, prior relapsers or partial responders. They were divided into three branches: 4 wks PR (lead-in), then PR-placebo 44 wks 4 wks PR (lead-in), then PR-BOC 32 wks 4 wks PR (lead-in), then PR-BOC 44 wks The best rate, of more than 65%, was achieved with 48 weeks of PEG-RBV and 44 weeks of boceprevir. Compared to the control group, treated with PEG-RBV with an rate of 21%, it is estimated that the association of boceprevir increases the rate to 66%. For relapsers there is a 29% to 75% increase in the (Fig. 6) and for partial response patients an increase from 7 to 52% (Fig. 7). It can be appreciated that for relapsers the combination of PIs has become imperative, while for partial response patients further studies are needed in order to decide whether the association of a PI is sufficient. Unfortunately, the risk of developing resistance to a PI is very high, therefore it has been decided that for nonresponders with a low degree of fibrosis (F1-F2) therapy should be postponed until the release of new molecules that could improve the response rate. PI resistance develops in half the patients, compromising future regimens that contain new molecules (nucleoside or non-nucleoside NS5B polymerase inhibitors, NS5A inhibitors) and need the association of a PI. Triple therapy can be used for patients with a high degree of fibrosis (F3, F4), at risk for progression to HCC PR 48 PR36B32 PR48B44 Fig. 6. The rates using boceprevir for previous relapse or partial responder patients. 46% increase in Fig. 7. Improving rates in relapsers.
6 122 Cristina Popescu et al. 6 b. Using telaprevir in previously treated patients The PROVE 3 study [12] enrolled 453 previously treated patients (relapsers, non-responders, breakthrough). The rates analysis for various regimens is presented in Fig. 8. If we look separately at rates for triple and bitherapy, for relapsers and non-responders, we can conclude: 1. The rate for relapsers increases from %, in the case of bitherapy to 69% for triple therapy, an addition of 49% (2.7 times higher) 2. The rate for non-responders increases from 9 to 39% by adding telaprevir to the bitherapy. As a follow-up to the ADVANCE study, the REALIZE Phase III study enrolled 663 previously treated patients, divided into 3 arms: T12/PR48, lead-in PR4 + 12T/PR 44 and PR48 (Fig. 9). The rates were: 64%, 66% and 17%, respectively. Therefore, the currently agreed regimen for triple therapy is 12 weeks of telaprevir and PEG-RBV, followed by 36 weeks of PEG-RBV. Analyzing patient categories: relapsers, partial responders and null responders showed: for relapsers rates of 24% for PEG- RBV, compared to 83% and 88% for the two regimens containing telaprevir (Fig. 1) for partial responders rates of 15% with SoC, 59% and 54% with triple therapy (Fig. 11) for null responders rates of 5% and 29% with SoC and 33% with triple therapy (Fig. 12). As with boceprevir- based regimens, using telaprevir in null- responders increases the risk of resistance to PIs, which will compromise future DAA regimens. 45% increase in Fig. 8. Improving rates for partial response patients relapser non-responder breakthrough T12PR24 T24PR48 T24P24 PR48 Fig. 9. rates for various telaprevir regimens.
7 7 Trends in Hepatitis C Virus Infection Therapy Increasing with 64% bitherapy triple therapy Fig. 1. Improving rates for relapsers Increasing with 39 % bitherapy triple therapy Fig. 11. Improving rates for partial responders bitherapy triple therapy Increasing with 24% Fig. 12. Improving rates for null responders. D. PI BASED REGIMENS APPROVED BY INTERNATIONAL GUIDELINES In late 11, the American Association for the Study of Liver Diseases (AASLD) amended therapeutic guidelines for HCV infected patients, introducing boceprevir and telaprevir in both naive and previously treated patients [14]. The same changes were published in early 12 in the UK [15]. D.1. BOCEPREVIR- BASED REGIMEN Boceprevir therapy is always associated with PEG-RBV, after 4 weeks of lead-in. The total duration of treatment is presented in Table I.
8 124 Cristina Popescu et al. 8 D.2. TELAPREVIR- BASED REGIMEN Telaprevir based regimens are always associated with PEG-RBV. Telaprevir and PEG-RBV are initiated simultaneously and continued for 12 weeks. The duration of the subsequent PEG-RBV treatment is presented in Table II. E. IMPROVING RATES WITH PROTEASE INHIBITORS Numerous studies using protease inhibitors have been published recently. New molecules are being studied, besides the already approved boceprevir and telaprevir. Table III shows some of the recently conducted studies, that used PIs in naive and previously treated patients. F. ADVERSE EFFECTS OF PROTEASE INHIBITORS The main adverse effects of boceprevir and telaprevir are presented in Table IV. We only listed the adverse events reported for regimens subsequently included in the current guidelines. The main side-effects associated with boceprevir are: dysgeusia (which does not require changes in treatment regimen), anaemia and neutropenia. Telaprevir has slightly different side- effects, with an increase in skin rash and anorectal symptoms. The rash leads to discontinuation of telaprevir in 5 7% of cases. The rash could be eczematous and pruritic, and in about 5% of cases appears in the first month of treatment. The anorectal symptoms are rarely a cause of discontinuation. Because of the risk of resistance, dose reduction for boceprevir and telaprevir should not be used. Table I Therapeutic algorithm for boceprevir- based regimens HCV RNA Duration of therapy S8 S24 Naive patients undetectable undetectable 4 wks lead-in PEG-RBV + 24 wks triple therapy detectable undetectable 4 wks lead-in PEG-RBV + 32 wks triple therapy + 12 wks PEG-RBV Naive patients, without risk factors for poor outcome;viral load after lead-in. If viral load is undetectable, the patient will receive biotherapy. Naive patients, with cirrhosis, 44 wks of triple therapy. Naive patients, with cirrhosis,viral load at 4 wks has not decreased by at least 1 log, discontinuation of therapy to prevent risk of resistance. Therapy failure (nonresponder undetectable undetectable 4 wks lead-in PEG-RBV + and relapser) detectable undetectable 32 wks triple therapy + 12 wks PEG-RBV Patients with cirrhosis and null-responders, treated with 44 wks of triple therapy. Patients with cirrhosis and null-repsponders, viral load after lead-in has not decreased by at least 1 log, discontinuation of therapy to prevent risk of resistance. If viral load> 1 UI/ml at S 12, stop therapy Detectable viral load at S24, stop therapy Boceprevir dose is mg x 3/day Table II Therapeutic algorithm for telaprevir- based regimens HCV-RNA Duration of therapy S4 S12 Naive patients and relapsers undetectable undetectable 12 wks triple therapy + 12 wks PEG-RBV detectable detectable/undetectable 12 wks triple therapy + 36 wks PEG-RBV R Partial and null responders Undetectable or <1 Undetectable or <1 UI/ml 12 wks triple therapy + UI/ml 36 wks PEG-RBV Patients with cirrhosis, partial and null responders will receive 48 wks of therapy, regardless of EVR. For patients with undetectable VL at S12, but under 1 UI/ml, repeat VL at S24. If positive, regardless of value, stop therapy. VL>1UI/ml at S4 or S12 requires stopping all regimens
9 9 Trends in Hepatitis C Virus Infection Therapy 125 Vierling J (16) NEXT-1 nerlaprevir + PR 12NVR/PR/12PR Table III Studies with Pis based regimens Study Year Sample naïve patients relapsers nonresponders % Okanoue T, (17) Telaprevir+PR 12T/24PR Nelson D.R (18) ZENITH study telaprevir +PR 12VX-222/T/PR Gordon S.C (19) Boceprevir+PR 4PR/24BPR/PR Larrey DG() Danoprevir+PR 2DNPPR/46PR Ogert R.A (21) (NEXT-2, RESPOND-2) Boceprevir + PR Vierling JM (22) PROVIDE study Boceprevir + PR 4PR/44BPR McCone J (23) Treatmentnaive black patients from SPRINT-2 Boceprevir + PR 4PR/44BPR Mann M (24) Vaniprevir (MK-79) + PR 4MK-79PR44PR 11 Japan (197 naïve, 3 trtfailure) 1 France Germany %.6% (% cumulative RBV) % 83% (from 197 patients) % 15 (197 naïve) 66% G1b 53% G1a 88.1%, 92.8% (% cumulative RBV) 78% (from 3 patients) 73% G1b 64% G1a 34.4% 45.5% (% cumulative RBV) 46 41% AT EOT.svr not available yet % % Table IV The main adverse effects Boceprevir(6,11) SPRINT 2/RESPOND 2 (response guided therapy) Telaprevir (9, 1, 13) ADVANCE, REALISE, ILLUMINATE (T12PR) Serious adverse events 1 11% 9 12% Discontinuation due to adverse events 8 12% 1 18% Anorectal symptoms NR 8 15% Dysgeusia 37 43% 12% Anaemia 43 49% 3 39% Neutropenia 19 24% 14% Rash 17 25% 37% Fatigue 53 55% 55 68% Pruritus 18 24% 5 52% Nausea 43 48% 35 47% Diarrhoea 22 23% 25 3% Anaemia during PI treatment The use of PIs is associated with a 25% increase in the rate of anaemia. Only 3 7% of the patients who developed anaemia during PI treatment registered severe anaemia (grade 3 or 4 haemoglobin level below 8 g/dl). Only 2 3% of the patients discontinued the treatment. In boceprevir studies, anaemia was treated with erythropoietin but in studies using telaprevir, the use of erythropoietin was forbidden. For telaprevir studies, the management of anaemia meant reducing the ribavirin dose, which did not induce a decrease in the rate.
10 126 Cristina Popescu et al. 1 CONCLUSIONS 1. For relapse patients, it is highly advisable to use a protease inhibitor (boceprevir or telaprevir) for the next therapeutic regimen. The association of boceprevir and telaprevir doubles the rate. 2. The rate for non-responders is much lower than the rate for relapsers, with an increased risk of PI resistance. It is therefore recommended, if the fibrosis is not very advanced to postpone therapy until new molecules are approved. 3. Determining the IL28b polymorphism is useful in choosing the right regimen for naive patients. Patients with unfavourable IL28b genotypes are candidates for triple therapy. 4. The rates for naive patients are close to % with the use of protease inhibitors associated to peginterferon-ribavirin. Standardul de aur în tratamentul hepatitei cronice cu VHC a fost până în 11 terapia combinată peginterferon-ribavirină, cu o rată a răspunsului virusologic susţinut () de 5%. În 11 FDA şi EMEA au aprobat o nouă clasă de antivirale inhibitorii de protează HCV-NS3. În prezent, sunt disponibile două molecule: boceprevir şi telaprevir. Inhibitorii de protează sunt utilizaţi în asociere cu peginterferon şi ribavirină, acestea din urmă rămânând în continuare componente vitale ale terapiei antivirale în hepatita cronică cu VHC, care actualmente din biterapie tinde să devină triterapie. Inhibitorii de protează cresc semnificativ rata de la pacienţii naivi, dar şi la relapseri. Din cauza riscului crescut de apariţie a rezistenţei la inhibitorii de protează, null-responderii anteriori nu sunt candidaţi la triplă terapie iar rata de este încă foarte scăzută la aceşti pacienţi. Corresponding author: Prof. Victoria Aramă, Matei Balş National Institute of Infectious Diseases, 1, Calistrat Grozovici, 2115, Bucharest, Romania ralsan@gmail.com REFERENCES 1. LAVANCHY D., The global burden of hepatitis C, Liver Int 9; 29 (Suppl. 1): McHUTCHISON J.G., LAWITZ E.J., SHIFFMAN M.L. et al., Peginterferon alfa-2b or alfa- 2a with ribavirin for treatment of hepatitis C infection, N Engl J Med 9; 361: HADZIYANNIS S.J., SETTE H. Jr., MORGAN T.R. et al., for PEGASYS International Study Group, Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med 4;1: BROK J., GLUUD L.L., GLUUD C., Meta-analysis: Ribavirin Plus Interferon vs. Interferon Monotherapy for Chronic Hepatitic C an Updated Cochrane Review, Alimentary Pharmacology & Therapeutics, 1; 32 (7): KWO P.Y., LAWITZ E.J., MCCONE J. et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, Lancet 1; 376: POORDAD F., MCCONE J. Jr., BACON B.R. et al., Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med 11; 364: McHUTCHISON J.G., EVERSON G.T., GORDON S.C. et al., Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection, N Engl J Med 9; 36: HEZODE C., FORESTIER N., DUSHEIKO G. et al., Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 9; 36: JACOBSON I.M., McHUTCHISON J.G.,DUSHEIKO G. et al., Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med 11; 364: SHERMAN K., FLAMMS, AFDHAL N. et al., Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection, N Engl J Med 11, 365, BACON B.R., GORDON S.C., LAWITZ E. et al., Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med 11; 364: McHUTCHISON J.G., MANNS M., MUIR A. et al., Telaprevir for Previously Treated Chronic HCV Infection, N Engl J Med 1, 362, ZEUZEM S., ANDREONE P., POL S. et al., Telaprevir for retreatment of HCV infection, N Engl J Med 11; 364:
11 11 Trends in Hepatitis C Virus Infection Therapy GHANY M.G., NELSON D.R., STRADER D.B. et al., An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 11 Practice Guideline by the American Association for the Study of Liver Diseases, Hepatology 11, RAMACHANDRAN P., FRASER A., AGARWAL K. et al., UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients, Aliment Pharmacol Ther 12; 35: VIERLING J.M. et al., Once daily nerlaprevir (NVR; SCH 9518) and ritonavir (RTV) in Combination with Peginterferon alfa- 2b/Ribavirin (PR) for 12 weeks plus 12 weeks PR in Treatment- Naïve Patients with HCV Genotype-1 (G1): results from NEXT-1, a Phase 2 Study, AASLD, OKANOUE T. et al., Telaprevir in combination with peginterferon alfa 2b and ribavirin therapy for genotype 1 chronic HCV patients: phase 3 study in Japan, AASLD, NELSON D.R. et al., VX-222/telaprevir in combination with peginterferon- alfa 2a and ribavirin in treatment- naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, 12 interim analysis, AASLD, GORDON S.C. et al., Effect of Baseline Viral load (VL) on response to Boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (PR) in patients infected with HCV genotype 1, AASLD, 11.. LARREY D.G. et al., High sustained virological response () rate for danoprevir for only 14 days associated with peginterferon alpha 2a and ribavirin in treatment chronic HCV genotype 1 patients, AASLD, OGERT R.A., Genotypic and phenotypic correlates of resistance in HCV genotype 1a and 1b infected patients treated with boceprevir plus peginterferon alpha and ribavirin, AASLD, VIERLING J.M. et al., Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study, AASLD, McCONE J. et al., Treatment-Naïve Black Patients Treated with Boceprevir (BOC) Combined with Peginterferon alfa-2b + Ribavirin (PR): Results from HCV SPRINT-2, AASLD, MANNS M. et al., Sustained Viral Response () Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir (MK-79), a NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days, AASLD, 1. Received March 26, 12
Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationBest of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS
Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationCurrent Standards in the Treatment of Chronic Hepatitis C
REVIEW ARTICLE Current Standards in the Treatment of Chronic Hepatitis C Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem SUMMARY Background: In Germany, 0 000 to 500 000 people are chronically infected
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationMany promising small molecule inhibitors directed
GASTROENTEROLOGY 2012;142:1351 1355 Will Interferon-Free Regimens Prevail? Christoph Welsch Stefan Zeuzem Department of Internal Medicine I, J. W. Goethe University Hospital, Frankfurt/Main, Germany Many
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationTreatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon
Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies Advances in treatment of HCV Dr John F Dillon Disclosure slide I have received consulting fees and Honoraria from MSD, Abbott,
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationEstimates suggest that if 1998 treatment practices were
n repts n A Review of Standard and Newer Treatment Strategies in Hepatitis C Tram T. Tran, MD Abstract Chronic infection with hepatitis C virus (HCV) is common, but underdiagnosed and undertreated wldwide.
More informationTITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update
TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update DATE: 02 January 2015 RESEARCH QUESTION What is the
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More informationBackground: Narlaprevir (SCH )
Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationDirect-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
DOI 10.1007/s10620-011-1604-3 ORIGINAL ARTICLE Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use Paul J. Gaglio Noah Moss Camille McGaw John Reinus Received: 15 December 2010
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationMonth/Year of Review: November 2011 End date of literature search: 4 th Quarter alone
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: November 2011 End date of literature
More informationTreatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
Published 24 February 2012, doi:10.4414/smw.2012.13516 Cite this as: Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir Swiss Association for the Study
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationEfficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
Journal of Viral Hepatitis, 2012, 19, e134 e142 doi:10.1111/j.1365-2893.2011.01528.x Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic
More informationHepatitis C Prior Authorization Policy
Hepatitis C Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationFor the RESPOND-2 Investigators
HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationReview Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection
Antiviral Therapy 211; 16:1187 121 (doi: 1.3851/IMP1934) Review Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection Peter Ferenci 1 *, K Rajender Reddy 2 1 Department
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationWHO Global Hepatitis Program. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries
WHO/HIV/201433 World Health Organization 2014 Global Hepatitis Programme Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries PICO 7: Treatment
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationInterferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives
TAJ December 2008; Volume 21 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review Article Interferon-Based Therapy for Chronic Hepatitis C : Present and Future Perspectives
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationCurrent Standard of Care for Naïve HCV Patients (SVR)
Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationEmerging Therapies for Hepatitis C
Gut and Liver, Vol. 8, No. 5, September 2014, pp. 471-479 Review Emerging Therapies for Hepatitis C Do Young Kim, Sang Hoon Ahn, and Kwang-Hyub Han Department of Internal Medicine, Yonsei University College
More informationChanging Direction Towards More Effective HCV Treatment
Changing Direction Towards More Effective HCV Treatment By: Prof.Dr.Abdel fattah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine The most common disease in the world HCV infects almost
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationNew Developments in the Treatment of Hepatitis C Virus Infection from Digestive Disease Week 2011
J u n e 2 0 1 1 A S P E C I A L M E E T I N G R E V I E W E D I T I O N V o l u m e 7, I s s u e 6, S u p p l e m e n t 1 0 New Developments in the Treatment of Hepatitis C Virus Infection from Digestive
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More information